Poolbeg Pharma PLC (LON:POLB – Get Free Report)’s stock price reached a new 52-week low during trading on Thursday . The company traded as low as GBX 3.51 ($0.04) and last traded at GBX 3.68 ($0.05), with a volume of 2319499 shares traded. The stock had previously closed at GBX 3.78 ($0.05).
Analysts Set New Price Targets
Separately, Shore Capital restated a “house stock” rating on shares of Poolbeg Pharma in a research note on Thursday, January 2nd.
Check Out Our Latest Stock Analysis on POLB
Poolbeg Pharma Trading Down 2.8 %
Poolbeg Pharma Company Profile
Poolbeg Pharma plc is focussed on the development and commercialisation of innovative medicines targeting serious diseases with a high unmet medical need. Its model focusses upon developing its exciting clinical assets and commercialising approved and marketed drugs to support the growth of the Company and the development of its robust pipeline of innovative products, thereby driving significant value creation.
Poolbeg is led by an experienced leadership team with a history of delivering significant shareholder value.
See Also
- Five stocks we like better than Poolbeg Pharma
- How to Invest in the Best Canadian Stocks
- Volatility Is Back: 3 Stocks To Cushion the S&P 500’s Swings
- How to Effectively Use the MarketBeat Ratings Screener
- 2 Catalysts That Could Push NVIDIA Stock Up 30% This Year
- Are Penny Stocks a Good Fit for Your Portfolio?
- Do GM Stock Buybacks Make the Stock Buyable For Investors?
Receive News & Ratings for Poolbeg Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Poolbeg Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
